Prion Protein Inhibitor

Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC₅₀ of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases.

ARN1468 (compound 5) is an orally active and potent SerpinA3n inhibitor. ARN1468 can inhibit serpins activity would set the protease free to further reduce prion accumulation. ARN1468 shows anti-prion effect in ScGT1 RML, ScGT1 22L, ScN2a RML, and ScN2a 22L cell lines, with EC₅₀ values of 8.64, 19.3, 11.2, and 6.27 μM.

BiCAPPA is the first bivalent antiprion ligand. BiCAPPA can decrease infectious conformational form of prion protein (PrP^Sc) from scrapie-infected cells, with an EC₅₀ of 0.32 μM.

IND24 is a potent antiprion agent with an EC₅₀ value of 1.27 µM. IND24 decreases abnormal, misfolded, pathogenic forms of benign normally occurring prion protein on the cell surface or inside the cell.

Etidaligide sodium scrambled negative control is the sequence scrambled negative control of Etidaligide sodium.

1-(4-Methoxyphenyl)-3-methyl-1H-pyrazol-5(4H)-one (Compound 2) has antiprion activity in ScN2a and F3 cells with IC₅₀ values of 13 nM and 25 nM, respectively.

Erisonersen, an antisense oligonucleotide, is a prion protein synthesis reducer. It is used for the study of Prion disease.

IND45193 is a compound used to inhibit prion disease, with activity in reducing PrP(Sc) levels. In cells infected with prions, IND45193 can reduce PrP(Sc) levels, and its activity was determined through screening of multiple cell types and concentration-effect relationship studies.

IND81 is an orally active antiprion with IC₅₀ value of 1.95 μM. IND81 reduces abnormal, misfolded, disease-causing forms of benign prion proteins that are normally present on or within cells.

Anti-Mouse/Human PrP/prion protein Antibody (TW1) is a mouse-derived IgG2a type antibody inhibitor, targeting to mouse/human PrP/prion protein. Anti-Mouse/Human PrP/prion protein Antibody (TW1) binds to both PrPc (cellular prion protein) and PrPSc (Scrapie Prion Protein) and blocks the interaction of prion protein with tau protein. Anti-Mouse/Human PrP/prion protein Antibody (TW1) can be used for the researches of Alzheimer’s disease (AD).

Radotinib-d₆ is deuterium labeled Radotinib (HY-15728). Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC₅₀ of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases.

Erisonersen sodium, an antisense oligonucleotide, is a prion protein synthesis reducer. It is used for the study of Prion disease.

Radotinib (IY-5511) dihydrochloride is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC₅₀ of 34 nM. Radotinib dihydrochloride has anti-prion and anti-tumor activities. Radotinib dihydrochloride can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib dihydrochloride can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases.

6-Amino-8-trifluoromethylphenanthridine (6A-8tFP) is an antiprion agent and a derivative of 6-aminophenanthridine (HY-135189). It inhibits protein folding activity of the ribosome (PFAR) when used at a concentration of 150 μM.2 6A-8tFP directly competes with protein substrates for the ribosomal active site.